SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

Poseida Therapeutics shares are trading lower after the company announced the FDA has placed a clinical hold on the company's Phase 1 clinical trial for P-PSMA-101 in metastatic castrate-resistant prostate cancer.

Benzinga · 08/18/2020 10:32